AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24657065 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients aged <80 years)
Number of subjects: 290
Study 24657127 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 1250
Study 24657127 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1250
Study 24657227 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on knowledge of CMS reimbursement rates
Number of subjects: 97
Study 24657227 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on impact of cost beliefs on ordering behavior
Number of subjects: 97
Study 24657227 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of costs accuracy
Number of subjects: 97
Study 24657695 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter heart valve (THV)
Number of subjects: 506
Study 24657719 — intervention group
Group type: EXPERIMENTAL
Intervention: OAcPec-rEPA
Number of subjects: 25
Study 24657993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1492
Study 24657993 — intervention group
Group type: EXPERIMENTAL
Intervention: pPCI
Number of subjects: 1492
Study 24657993 — intervention group
Group type: COMPARATOR
Intervention: No reperfusion
Number of subjects: 1492
Study 24657993 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis
Number of subjects: 1492
Study 24657993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis (beyond 90 minutes of call)
Number of subjects: 1492
Study 24657993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis (early population)
Number of subjects: 1492
Study 24658821 — intervention group
Group type: EXPERIMENTAL
Intervention: pan-KIR2D blockade with IPH2101
Number of subjects: 0
Study 24659579 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 70
Study 24659579 — intervention group
Group type: COMPARATOR
Intervention: Untreated KS
Number of subjects: 70
Study 24659579 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 70
Study 24659579 — intervention group
Group type: EXPERIMENTAL
Intervention: KS males
Number of subjects: 70
Study 24659579 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study 24659579 — intervention group
Group type: EXPERIMENTAL
Intervention: KS patients
Number of subjects: 70
Study 24659631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 24660224 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 409
Study 24660224 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 409
Study 24661373 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR TKI patients (sunitinib or sorafenib)
Number of subjects: 80
Study 24661373 — intervention group
Group type: COMPARATOR
Intervention: Patient controls (mRCC not receiving systemic treatment)
Number of subjects: 80
Study 24661373 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 24661577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program (3 months)
Number of subjects: 48
Study 24661577 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (6 individuals)
Number of subjects: 48
Study 24661633 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cell transplantation (UC-MSCT)
Number of subjects: 40
Study 24661732 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 89
Study 24661732 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 89
Study 24661748 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 2500
Study 24661748 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 2500
Study 24661748 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-cost model
Number of subjects: 2500
Study 24661748 — intervention group
Group type: COMPARATOR
Intervention: Fixed-cost model
Number of subjects: 2500
Study 24661784 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor concentrate (C1-INH) at 20 IU/kg
Number of subjects: 57
Study 24661824 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 21
Study 24661824 — intervention group
Group type: COMPARATOR
Intervention: Hybrid Iterative Reconstruction (IR)
Number of subjects: 21
Study 24661824 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based Iterative Model Reconstruction (IMR)
Number of subjects: 21
Study 24661823 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA) findings
Number of subjects: 3015
Study 24661823 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up coronary CTA at 2 years
Number of subjects: 3015
Study 24661823 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure, serum lipid, and C-reactive protein levels
Number of subjects: 3015
Study 24662399 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable transcatheter aortic valve (TAV)
Number of subjects: 55
Study 24662448 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 102
Study 24662454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus cisplatin and vinorelbine (chemotherapy)
Number of subjects: 971
Study 24664095 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 166
Study 24664095 — intervention group
Group type: COMPARATOR
Intervention: PM
Number of subjects: 166
Study 24664277 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker
Number of subjects: 33
Study 24664935 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα antagonist therapy
Number of subjects: 708
Study 24664935 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles enthesis hypervascularization by power Doppler
Number of subjects: 708
Study 24664935 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of work days missed
Number of subjects: 708
Study 24665133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell patients
Number of subjects: 0
Study 24665133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell patients during acute pain crisis
Number of subjects: 0
Study 24665133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell patients recovered from pain crisis
Number of subjects: 0
Study 24665133 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 24665972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM)
Number of subjects: 647
Study 24665972 — intervention group
Group type: COMPARATOR
Intervention: Continuous monitoring (CM) devices
Number of subjects: 647
Study 24665992 — intervention group
Group type: EXPERIMENTAL
Intervention: Protecta XT dual-chamber ICD (n = 114)
Number of subjects: 246
Study 24665992 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator with cardiac resynchronization therapy (n = 132)
Number of subjects: 246
Study 24666542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84
Study 24666542 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 84
Study 24666686 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 0.2 mg·kg(-1) per 8 h in neonates
Number of subjects: 56
Study 24666686 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion dosing
Number of subjects: 56
Study 24666686 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemate of methadone
Number of subjects: 56
Study 24666686 — intervention group
Group type: EXPERIMENTAL
Intervention: EDDP and EMDP metabolites
Number of subjects: 56
Study 24667011 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential application of four preventive measures
Number of subjects: 1935
Study 24667717 — intervention group
Group type: EXPERIMENTAL
Intervention: vintafolide
Number of subjects: 49
Study 24668327 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus-based regimens
Number of subjects: 0
Study 24668831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryocontact therapy
Number of subjects: 0
Study 24668831 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24668858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg orally three times a week
Number of subjects: 7
Study 24669961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 international units/day)
Number of subjects: 58
Study 24669961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24669960 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rt-PA treatment
Number of subjects: 369
Study 24669965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients
Number of subjects: 234
Study 24669965 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 234
Study 24670013 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Babies Breathe (HBB) training program
Number of subjects: 30000
Study 24670013 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB/ENC training and quality monitoring and improvement package
Number of subjects: 30000
Study 24670075 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management (SWM) measure
Number of subjects: 640
Study 24670075 — intervention group
Group type: EXPERIMENTAL
Intervention: SWM scores
Number of subjects: 640
Study 24670085 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children with MetS
Number of subjects: 264
Study 24670085 — intervention group
Group type: EXPERIMENTAL
Intervention: UFC
Number of subjects: 264
Study 24670085 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA index
Number of subjects: 264
Study 24670085 — intervention group
Group type: EXPERIMENTAL
Intervention: SC
Number of subjects: 264
Study 24670165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378) at doses of 400 mg or more per day
Number of subjects: 130
Study 24670428 — intervention group
Group type: EXPERIMENTAL
Intervention: SootherMask (SM) with Respimat Soft Mist Inhaler (SMI) and InspiraChamber (IC)
Number of subjects: 13
Study 24670608 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide at 150 mg/m(2)/day on days 1-7 and days 15-21 during each 4-week cycle
Number of subjects: 60
Study 24670710 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally subcutaneous implantable defibrillator (S-ICD)
Number of subjects: 472
Study 24670864 — intervention group
Group type: EXPERIMENTAL
Intervention: fenestrated and/or branched endovascular repair (f/b-EVAR)
Number of subjects: 268
Study 24671104 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 6726
Study 24671104 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in BMI
Number of subjects: 6726
Study 24671709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-choline diet
Number of subjects: 79
Study 24671831 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-1127 (glyburide for injection)
Number of subjects: 10
Study 24671981 — intervention group
Group type: EXPERIMENTAL
Intervention: STONE score (0-13) - low probability (score 0-5)
Number of subjects: 1531
Study 24671981 — intervention group
Group type: EXPERIMENTAL
Intervention: STONE score (0-13) - moderate probability (score 6-9)
Number of subjects: 1531
Study 24671981 — intervention group
Group type: EXPERIMENTAL
Intervention: STONE score (0-13) - high probability (score 10-13)
Number of subjects: 1531
Study 24674873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib at 400 mg/day plus exemestane at 25 mg/day
Number of subjects: 42
Study 24674873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib at 300 mg/day plus exemestane at 25 mg/day
Number of subjects: 42
Study 24674874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (400 mg/day) plus Letrozole (2.5 mg/day)
Number of subjects: 16
Study 24674874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib plus Letrozole
Number of subjects: 16
Study 24674961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OCD
Number of subjects: 42
Study 24674961 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study 24675204 — intervention group
Group type: EXPERIMENTAL
Intervention: Innervated flap
Number of subjects: 166
Study 24675204 — intervention group
Group type: COMPARATOR
Intervention: Noninnervated flap
Number of subjects: 166
Study 24675204 — intervention group
Group type: COMPARATOR
Intervention: Single-innervated flap
Number of subjects: 166
Study 24675204 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaps harvested from the middle phalanx
Number of subjects: 166
Study 24675585 — intervention group
Group type: EXPERIMENTAL
Intervention: TB LAM test
Number of subjects: 1013
Study 24675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine TB LAM test plus sputum smear microscopy
Number of subjects: 1013
Study 24675585 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive TB LAM test
Number of subjects: 1013
Study 24675657 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine
Number of subjects: 160
Study 24675657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraethylammonium
Number of subjects: 160
Study 24675657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin, Acetylcholine, Sodium Nitroprusside
Number of subjects: 160
Study 24675918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion at 4±2°C for 20 minutes
Number of subjects: 35
Study 24676282 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers
Number of subjects: 1260
Study 24676282 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1260
Study 24676282 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1260
Study 24676282 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1260
Study 24676282 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 1260
Study 24676783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD) patients
Number of subjects: 38
Study 24677205 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist with disengaged feelings
Number of subjects: 2
Study 24677205 — intervention group
Group type: COMPARATOR
Intervention: Therapist with engaged feelings
Number of subjects: 2
Study 24678741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet assisted TKA
Number of subjects: 80
Study 24678741 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet assisted TKA
Number of subjects: 80
Study 24678902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8 for 2 induction cycles.
Number of subjects: 70
Study 24678902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 on day 1 and oral vinorelbine 20 mg on days 1, 3 and 5 during concomitant radiotherapy 2 Gy daily, 5 days/week for a total of 66 Gy.
Number of subjects: 70
Study 24678911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pac-IFicO programme
Number of subjects: 500
Study 24679131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led follow-up program
Number of subjects: 4
Study 24679462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (60 Gy of conventional irradiation to the surgical bed for 6 weeks)
Number of subjects: 1005
Study 24679462 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 1005
Study 24679462 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 1005
Study 24680929 — intervention group
Group type: EXPERIMENTAL
Intervention: Microaneurysm turnover
Number of subjects: 0
Study 24680929 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical macular edema identified by OCT and mfERG
Number of subjects: 0
Study 24680929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 0
Study 24681017 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) using the Symplicity Flex™ catheter
Number of subjects: 59
Study 24681017 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 59
Study 24681609 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A silicone hydrogel lenses
Number of subjects: 205
Study 24681911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically abnormal but normal weight (MANW)
Number of subjects: 1012
Study 24681993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine (TDF-FTC)
Number of subjects: 0
Study 24681993 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine (ABC-3TC)
Number of subjects: 0
Study 24681993 — intervention group
Group type: COMPARATOR
Intervention: Control group (not carrying HLA-DQ3)
Number of subjects: 0
Study 24682387 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical stroke risk assessed using CHADS2 score (≥2)
Number of subjects: 10094
Study 24682387 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical bleeding risk assessed using ATRIA score (≥5)
Number of subjects: 10094
Study 24682387 — intervention group
Group type: COMPARATOR
Intervention: Physician estimates of stroke risk
Number of subjects: 10094
Study 24682387 — intervention group
Group type: COMPARATOR
Intervention: Physician estimates of bleeding risk
Number of subjects: 10094
Study 24682387 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation use among patients with high stroke risk
Number of subjects: 10094
Study 24682387 — intervention group
Group type: COMPARATOR
Intervention: Impact of physician and empirical estimates of bleeding on treatment choice
Number of subjects: 10094
Study 24682512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 85
Study 24682613 — intervention group
Group type: EXPERIMENTAL
Intervention: Second consecutive LNG-IUS
Number of subjects: 204
Study 24683529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX) - resistance bands, 3 times weekly during chemotherapy
Number of subjects: 14
Study 24683529 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 14
Study 24684464 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (3180 kJ/d) for 56 days
Number of subjects: 39
Study 24684466 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide treatment for 18 months
Number of subjects: 20
Study 24684783 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld echocardiography (HHE)
Number of subjects: 190
Study 24684783 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 190
Study 24684785 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg daily) and Carboplatin (AUC 6, later decreased to AUC 5 and AUC 4) every 3 weeks
Number of subjects: 25
Study 24685375 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched endograft treatment for arch aneurysms
Number of subjects: 38
Study 24685375 — intervention group
Group type: COMPARATOR
Intervention: Branched endograft treatment for arch aneurysms (early experience group)
Number of subjects: 38
Study 24685605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) in regular medical care
Number of subjects: 2500
Study 24685605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) in telemedicine-based coagulation service
Number of subjects: 2500
Study 24685605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) in both cohorts
Number of subjects: 2500
Study 24685661 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality traits (neuroticism, conscientiousness)
Number of subjects: 102
Study 24685661 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 102
Study 24685661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restraint of eating
Number of subjects: 102
Study 24686108 — intervention group
Group type: EXPERIMENTAL
Intervention: Exception from informed consent (EFIC) availability
Number of subjects: 191
Study 24686108 — intervention group
Group type: COMPARATOR
Intervention: Minority status
Number of subjects: 191
Study 24687068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm combining clinical decision score, d-dimer testing, and ultrasonography
Number of subjects: 406
Study 24687156 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stents with biodegradable polymer
Number of subjects: 0
Study 24687156 — intervention group
Group type: COMPARATOR
Intervention: Second-generation drug-eluting stents with durable polymer
Number of subjects: 0
Study 24687408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine (250 mg/m²) in a 6-h infusion plus cisplatin (35 mg/m²) on days 1 and 8 every three weeks
Number of subjects: 39
Study 24687408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine infusion plus cisplatin
Number of subjects: 39
Study 24687837 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPI low-risk group
Number of subjects: 958
Study 24687837 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPI intermediate-risk group
Number of subjects: 958
Study 24687837 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPI high-risk group
Number of subjects: 958
Study 24687837 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPI
Number of subjects: 958
Study 24688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-titer Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age
Number of subjects: 408
Study 24688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age
Number of subjects: 408
Study 24688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age, with or without a second dose at 18 months of age
Number of subjects: 408
Study 24689499 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 327
Study 24690111 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD outpatients
Number of subjects: 95
Study 24690111 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 95
Study 24691204 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 147